Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
THC + cannabidiol
- Development stage
- Phase 3
- Lead developer
- University Medical Center Groningen
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Sublingual
01
Overview
THC + cannabidiol (specifically referring to Transvamix®) is a standardized medicinal cannabis oil containing 10% delta-9-tetrahydrocannabinol (THC) and 5% cannabidiol (CBD). It is prepared as a magistral (compounded) formulation by specialist pharmacies in the Netherlands, such as Transvaal Apotheek and Felix Farma, using standardized plant material supplied by Bedrocan. The combination is administered sublingually and acts primarily as an agonist of cannabinoid receptors CB1 and CB2. It is being evaluated in clinical trials, including a Phase 2a study (NCT06518434) led by the University Medical Center Groningen (UMCG) for its potential anti-tumor activity in patients with advanced, untreatable hepatocellular carcinoma (HCC), as well as in a Phase 2 trial (C4EB) for the management of chronic pain and pruritus in patients with epidermolysis bullosa.
- Brand names
- Transvamix
- Other names
- cannabis oil (THC 10% / CBD 5%)delta-9-tetrahydrocannabinol + cannabidiolmedical cannabis oiltetrahydrocannabinol + cannabidiolTHC/CBD cannabis oil
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)FAAHGPR55 (G protein-coupled receptor 55)PPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on THC + cannabidiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on THC + cannabidiol.